FourThought Financial Partners LLC Sells 98 Shares of Novo Nordisk A/S (NYSE:NVO)

FourThought Financial Partners LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,463 shares of the company’s stock after selling 98 shares during the quarter. FourThought Financial Partners LLC’s holdings in Novo Nordisk A/S were worth $565,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of NVO. Jennison Associates LLC increased its holdings in Novo Nordisk A/S by 100.3% during the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after buying an additional 11,727,507 shares during the last quarter. Polen Capital Management LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $718,995,000. FMR LLC lifted its stake in Novo Nordisk A/S by 122.7% in the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares during the last quarter. Morgan Stanley grew its holdings in Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after purchasing an additional 4,526,199 shares during the period. Finally, Loomis Sayles & Co. L P increased its position in Novo Nordisk A/S by 91.7% during the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after buying an additional 4,350,862 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded down $0.97 during trading on Friday, hitting $123.05. 5,932,926 shares of the company were exchanged, compared to its average volume of 3,905,318. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a market capitalization of $552.19 billion, a P/E ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. The business’s 50 day moving average is $127.20 and its 200-day moving average is $113.10.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 92.21%. The business had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.